The positive efficacy data from the Phase 2b trial is a significant milestone for NeuroSense Therapeutics, likely leading to increased investor confidence and a higher stock price in the short term. As the lead drug candidate, PrimeC's success is critical to the company's future, making this news highly relevant and important to investors. The confidence score reflects the direct correlation between clinical trial outcomes and biotech stock movements, although long-term impacts depend on further trials and regulatory approvals.